Chapter 27: Inborn Errors of Metabolism

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome.

If you're listening to this right now, it probably means you are a college student currently staring down a massive textbook and getting ready to conquer clinical biochemistry.

Take a deep breath.

You are in exactly the right place.

We're going to treat this deep dive not as your standard audio show, but as a personalized one -on -one tutoring session designed specifically for you.

Exactly.

Our mission today is to master Chapter 27 of Clinical Biochemistry and Metabolic Medicine, the eighth edition.

We're talking about inborn errors of metabolism or IMMs.

And look, let's untack this.

We have a lot of complex pathways to cover today.

But by the end of this session, you're going to understand the logical flow from the normal pathways to the specific lab abnormalities they cause all the way down to patient management.

That is the goal.

So let's set a baseline for you.

Right, and we can skip the basic high school biology review because you already know how genes work.

What we really need to focus on is what happens when just one of those 50 ,000 gene pairs carries a mutation.

Because a single point mutation can cause an entire metabolic pathway to just collapse.

It really can.

These genetic variants range from being completely incompatible with life to producing tiny biochemical differences we can barely even detect.

And right in the middle of those two extremes are our inborn errors of metabolism.

Their prevalence is incredibly diverse too.

It is.

Depending on the specific disorder in the population, incidence ranges anywhere from one in 100 births down to one in 200 ,000.

Which is why understanding the underlying mechanism is so crucial for your exams and your future clinical practice.

You can't just memorize all of these.

No, you have to understand the machinery.

So let's start with the fundamental genetic blueprint and its metabolic consequences.

The textbook gives us a brilliant way to visualize this.

Imagine a factory assembly line.

Okay, I like this analogy.

Substance A is rolling down the belt and it needs to be converted into substance B.

The worker doing that specific job is enzyme X.

Now imagine you have a genetic defect and enzyme X never shows up for their shift.

The line breaks down.

Right, but what actually happens in the body?

This is the core concept you need to grasp.

Because when that worker is missing, it usually causes problems in one of three distinct ways.

First being, you get a deficiency of the final product.

Exactly, a deficiency of substance B.

The assembly line simply stops producing it.

For example, in a condition called congenital adrenal hyperplasia, an enzyme defect means the body cannot produce enough cortisol.

Okay, and the second consequence.

You get an accumulation of the precursor, substance A.

If enzyme X isn't there to process it, substance A just piles up on the conveyor belt.

This is exactly what happens in phenylketonuria, right?

PKU.

Yes, where the amino acid phenylalanine accumulates to toxic levels in the blood.

Right, so the precursor just overflows.

And then the third consequence is when that overflow spills into an adjacent factory line.

Precisely, diversion to an alternative pathway.

Let's say that piled up substance A can also be turned into substance C by a completely different enzyme worker.

Because A is piling up to massive levels, the body desperately pushes it all down that alternative route.

Causing substance C to accumulate.

Going back to our congenital adrenal hyperplasia example,

because the pathway to making cortisol is blocked,

all those precursor hormones get diverted into making androgens.

And this massive overproduction of androgens causes virilization, which is the inappropriate development of male physical characteristics.

But wait, if I'm thinking about how the body normally regulates itself with negative feedback, doesn't the brain realize cortisol is low and try to fix it?

It seems like that would actually make the whole situation worse.

You've hit the nail on the head.

Metabolic pathways are usually controlled by negative feedback from the final product.

The brain senses the dangerously low cortisol and screams at the adrenal glands to make more.

Which completely ramps up the production of the precursors.

Right.

But because the enzyme to actually make the cortisol is still broken, all that extra precursor just gets shunted into androgen production, severely aggravating the virilization.

It's a physiological vicious cycle.

It's like pressing the gas pedal all the way to the floor when the steering wheel is locked.

That's a great way to put it.

And it's important to remember, these genetic diseases don't exist in a vacuum.

Environmental and physiological factors can massively modify how they present.

Make hereditary hemochromatosis, where the body absorbs too much iron.

Women with this condition rarely show clinical features before menopause.

Why?

Because the natural iron lost during menstruation and pregnancy actually protects them by clearing out the excess iron.

It's a perfect example of how normal physiology alters pathology.

The textbook also highlights patients with plasma cholinesterase variants.

Oh, right.

These individuals are perfectly healthy and asymptomatic their entire lives until they undergo surgery and are given a specific muscle relaxant called succimothonium.

Because they lack the enzyme to break it down, they suddenly develop prolonged respiratory paralysis.

It's a terrifying condition known as suculine abnuaya.

Context is everything.

Which naturally brings us to the concepts of clinical importance, screening, and suspicion.

Why do we bother screening newborns for these conditions?

Well, some IEMs, like renal glycosuria or Gilbert syndrome, are generally harmless.

But others, like PKU and galactosemia, cause massive irreversible brain or organ damage if you miss them in those first few weeks of life.

So as a clinician, what makes a disease actually suitable for population screening?

The criteria are strict.

The disease shouldn't be clinically obvious at birth.

Otherwise, you wouldn't need a test to find it.

Crucially, early treatment must actually improve the outcome.

The test itself needs to be reliable too.

And you have to get the results back before that irreversible damage occurs.

In the UK, for instance, babies get a heel prick test between five and eight days old.

Blood spots are placed on a paper card to test for conditions like neonatal hypothyroidism and PKU.

And we can actually screen even earlier for high -risk groups using prenatal screening.

If a specific population has a high carrier rate like Tay -Sachs disease in Ashkenazi Jewish populations, doctors can test cultured fetal fibroblasts.

They might use amniocentesis in the second trimester or chorionic villus sampling even earlier in the first trimester.

But let's say a baby slips through the screening cracks or has a rare disorder we don't screen for.

When should you suspect an inborn error of metabolism?

You are looking for unusual, unexplained clinical features in an infant.

Early signs might include severe hypoglycemia, metabolic acidosis, failure to thrive, relentless vomiting, and enlarged liver and spleen.

Or even peculiar smells in the baby's nappy?

Yes.

Late signs, if the condition is missed, might be severe intellectual disabilities, refractory rickets that won't heal, or unexpected cataracts in a toddler.

If a baby presents acutely ill, it's often an enzyme abnormality.

You can't always test the enzyme directly in an emergency, but you can test indirectly.

Exactly.

For example, a massive spike in plasma ammonia points strongly toward a urea cycle disorder or an organic aciduria.

Okay, so if we find one of these defects, what are our treatment options?

The text maps out three main logical strategies.

First, limit the precursor intake like putting a child with PKU on a strict low -phenoline diet.

Second, supply the missing product like giving synthetic cortisol to a patient with congenital adrenal hyperplasia.

Or third,

remove the accumulated toxic product like actively removing ammonia from the blood in urea cycle disorders.

Keep those three therapeutic principles in mind.

They are the bedrock of patient management.

Now let's apply all this theory to our first major category.

Urea cycle disorders.

Right.

The urea cycle is the body's dedicated machinery for safely disposing of waste nitrogen.

If there's a genetic defect in this cycle, the toxic nitrogen builds up as severe hyperammonemia, dangerously high ammonia in the blood.

You'll also see respiratory alkalosis and a remarkably low plasma urea concentration.

Let me logic through that.

If there are ammonia's through the roof, but their urea is nearly zero,

that has to mean the conversion mechanism itself is physically broken.

The ammonia is trapped because it literally cannot be synthesized into urea.

Exactly, the cycle is stalled.

One of the most common genetic defects here is ornithine transcarbamylase or OTC deficiency, which is notably an X -linked condition.

Let's frame this as a clinical mystery arriving in your ER, just like the textbook's first case study.

You have a three -month -old boy brought in for failure to thrive and severe hypotonia.

He's incredibly floppy and weak.

Taking the family history, you learn they previously lost a male child at nine months old to an unexplained illness.

You order labs.

Plasma, sodium, and potassium are totally normal, but his urea is incredibly low at 0 .5 millimoles per liter when normal is 2 .5 to 7 .5.

And his ammonia.

It is massively high at 654 micromoles per liter.

Normal is less than 20.

You also run an amino acid analysis, which shows elevated erotic acid.

As a student, you should immediately connect these dots.

The combination of extremely high ammonia and exceptionally low urea in a neonate points directly to a urea cycle defect.

And the elevated erotic acid.

That is the smoking gun that confirms the pathway is blocked at a very specific point, ruling out other cycle defects.

Finally, the fact that he is a boy and he had a brother who died young perfectly fits the X -linked inheritance pattern of OTC deficiency.

The lab values are a direct mirror of the broken biochemical pathway.

It is incredibly satisfying when the physiology perfectly explains the pathology.

Let's move to our next major category.

Disorders of amino acid metabolism.

Picture another biochemical assembly line.

This time the aromatic amino acid pathway.

It all starts with the amino acid phenylalanine.

If you have a deficiency in the very first enzyme worker phenylalanine hydroxylase, or sometimes it's essential cofactor,

tetrahydrobiopterin phenylalanine cannot be converted into tyrosine.

So it accumulates.

This is phenylketonuria or PKU.

And this has fascinating downstream physical effects.

Because tyrosine is a necessary precursor for making melanin, patients with PKU often have significantly reduced melanin formation.

This presents clinically as pale skin, fair hair and blue eyes.

If undiagnosed, the toxic buildup of phenylalanine in the brain causes severe intellectual disabilities, irritability and seizures in the first weeks of life.

The treatment is a strict lifelong low phenylalanine diet and here's a crucial clinical pearl.

You must remind your patients that the artificial sweetener aspartame is actually metabolized into phenylalanine in the gut.

Yes, it can be toxic to them.

That's a detail you absolutely need to remember for the warts.

Okay, what if the defect is further down that exact same aromatic pathway?

Let's say phenylalanine successfully becomes tyrosine, but later on you have a deficiency of an enzyme called homogenetic acid oxidase.

This causes a condition called alkaptonuria.

Homogenetic acid accumulates in the tissues and when it polymerizes, it produces a dark pigment called alkapton.

Which leads to a truly bizarre and fascinating clinical presentation.

Over years, this dark pigment deposits in the body's cartilages causing them to physically darken a condition called ochrinosis.

You might literally see a bluish black discoloration in the cartilage of a patient's ears and it causes severe early onset arthritis.

Even wilder is how it affects the urine.

Right, if a patient's urine sits in a beaker and gradually becomes alkaline at room temperature, the homogenetic acid oxidizes into a literal black suspension.

Imagine being the first doctor to observe that.

Two other quick stops on this aromatic pathway.

Albinism is caused by a deficiency of tyrosinase, specifically in the melanocytes, causing severe photosensitivity and lack of pigment.

And homocystinuria is a deficiency of cystithionine synthase, which leads to progressive central nervous system dysfunction, eye cataracts, and a dangerously high risk of thrombosis or blood clots.

Another deeply fascinating disorder of amino acid metabolism is maple syrup urine disease.

This is an autosomal recessive condition where the body's machinery cannot properly decarboxylate the branched chain of amino acids,

specifically leucine, isoleucine, and baleen.

Because they can't be broken down, they accumulate massively in the plasma and spill into the urine.

The textbook describes how if you freeze the urine from one of these patients, a distinct layer of oil sits on top.

And that oil smells intensely sweet, exactly like maple syrup.

But the sweetness masks a devastating reality.

Those branched chain amino acids are incredibly toxic to the central nervous system.

If untreated, it causes severe neurological lesions and death within weeks.

These infants require a highly specialized diet low in leucine, isoleucine, and baleen.

Now, pivoting slightly, let's talk about how amino acids are transported across cell membranes in the kidneys.

The textbook gives a great mnemonic for the dibasic amino acids that share a transport mechanism.

COAL, COAL, cysteine, ornithine, orgenine, and lysine.

Keep that mnemonic handy.

In a condition called cystinuria, an autosomal recessive abnormality means the renal tubules simply cannot reabsorb these four specific amino acids, so they spill out into the urine.

Because cysteine is relatively insoluble, it precipitates in the urinary tract and forms painful kidney stones.

You manage this by aggressively hydrating the patient, alkalinizing their urine, or using a drug called D -penicillamine to increase solubility.

But you must distinguish this relatively harmless transport defect from cystinosis.

Right, cystinosis is a completely different fatal disorder where cysteine is actually stored inside the body cells, causing widespread tissue destruction.

The textbook also notes heart nub's disease.

This is a transport defect of neutral amino acids, particularly tryptophan.

Because our bodies normally convert some tryptophan into nicotinamide, a B vitamin, these patients present with symptoms that perfectly mimic pellagra.

They get a red, scaly rash on sun -exposed skin, ataxia, and confusion.

And before we leave amino acids entirely, remember that sometimes amino acids in the urine aren't a primary genetic defect, but secondary damage.

Like in Wilson's disease, copper deposition physically damages the renal tubules, causing all sorts of amino acids to non -specifically leak into the urine.

That's a great distinction between primary and secondary defects.

Let's move to our next category,

lysosomal disorders.

Lysosomes are the cell's internal recycling centers.

They are packed with hydrolase enzymes that break down complex molecules.

If one of those specific enzymes is genetically deficient, the complex molecules can't be recycled.

They just accumulate inside the cell, causing the organs to swell and fail.

The mucopolysaccharidosis, or MPSs, happen when you lack the enzymes to hydrolyze glycosaminoglycans.

These massive sugar chains build up in the liver, spleen, eyes, and bones.

For your exams, you definitely need to know the difference between Herler's syndrome and Hunter's syndrome.

Herler's, or MPSIH, is the more severe form and is autosomal recessive.

These patients develop short stature, coarse facial features, and notably corneal clouding in their eyes.

But Hunter's syndrome, or MPS2, is clinically unique because it is the only mucopolysaccharidosis inherited as an X -linked recessive trait,

and patients typically do not have corneal clouding.

Then we have the lipid storage disorders, where the recycling center fails to break down sphingolipids.

Classic examples include Tay -Sachs disease, Goucher's disease, and Niemann -Pick disease.

Clinically, because these lipids are literally stuffing the cells full, you're looking for massive organomegaly -enlarged liver and spleen skeletal abnormalities, and a very specific tragic finding on an eye exam.

The cherry -red macular spot, which is surrounded by pale, lipid -filled cells.

Exactly.

Let's shift gears to carbohydrate disorders.

This is where the biochemistry logic gets incredibly elegant.

Take galactosemia.

This is caused by a deficiency of the galactose -1 -phosphate uridotransferase enzyme.

We usually just call it Gal -1 -PUT.

Think about a newborn baby whose only food is milk.

Milk contains lactose.

In the gut, lactose breaks down into glucose and galactose.

But because this baby lacks Gal -1 -PUT, they literally cannot process the galactose.

It becomes trapped inside their cells, drawing in water and causing osmotic damage.

They develop relentless vomiting, failure to thrive, liver cirrhosis, and cataracts.

The only cure is immediately removing all milk and galactose from their diet.

Next are the glycogen storage diseases, and this is where you really see pathways cascading into one another.

Let's focus on type I, known as von Gierke's disease.

The missing enzyme here is glucose -6 -phosphatase.

To understand the profound impact of this, let's analyze another clinical mystery.

You're examining a four -year -old boy.

He has severe growth retardation and hepatomegaly.

His liver is massive.

You draw his fasting labs.

His fasting glucose is dangerously low at 2 .0 millimoles per liter when normal is 3 to 5 .5.

His lactic acid is high at 3 .7.

And his urate, or uric acid, is abnormally elevated at 0 .61.

Let's logic through the why here.

Why does a single missing enzyme in glycogen storage cause all of these totally different lab abnormalities?

It's a beautiful, terrible cascade.

Because he lacks glucose -6 -phosphatase, his liver is entirely unable to release glucose from its glycogen stores into the blood during a fast.

That directly causes the severe fasting hypoglycemia.

Because that normal gluconeogenesis pathway is essentially a dead end, the body's metabolism shifts gears to survive.

Leading to a massive overproduction of lactic acid, hence the lactic acidosis.

And here's the fascinating physiological connection.

That excess lactic acid in the blood travels to the kidneys, where it actually competes with uric acid for excretion.

The lactic acid blocks the uric acid from leaving the body in the urine, resulting in hypervirochemia in the blood.

See, every single abnormal number is connected to the same original broken mechanism.

Briefly, you should also be aware of type 2, Pomp's disease, which primarily affects the heart and skeletal muscles.

Type 3 is Forbes' quarry.

And type V is McCardell's disease, which is a muscle phosphorylase deficiency.

These patients get severe muscle cramps upon exertion.

And if the muscle breaks down, myoglobin leaks into their urine, turning it a dark burgundy red color.

Moving on, we need to discuss lipid oxidation and organic acidurias.

Organic acidurias occur when enzymes involved in the breakdown of amino acids, carbohydrates, or lipids are deficient.

Causing intermediate organic acids to build up.

A prime example is methylmalonic acidemia.

Let's look at a case presentation for this one.

A five -month -old girl is referred to your clinic for failure to thrive, profound lethargy, and convulsions.

You run her labs.

Her bicarbonate is severely low at 11 millimoles per liter, which immediately tells you she has a severe metabolic acidosis.

Her ammonia is massive, sitting at 721.

But the key to solving this mystery is her urine analysis.

It shows heavily increased ketones and the presence of methylmalonic acid.

Finding that methylmalonic acid in the urine

absolutely cements the diagnosis of methylmalonic acidemia.

The profound metabolic acidosis and the secondary hyperaminemia are classic downstream effects of the organic acids poisoning the system.

This case is a stark clinical reminder.

You must always, always consider an underlying inborn error of metabolism when an instant presents with failure to thrive an unexplained metabolic acidosis.

The text also highlights a very specific lipid oxidation defect called MCAD medium chain acyl -CoA dehydrogenase deficiency.

Let me explain why this one is so crucial.

Normally when we fast, our bodies switch to burning stored fat for energy.

But kids with MCAD lack the enzyme to break down medium chain fatty acids.

So imagine a toddler with MCAD gets a normal stomach bug, vomits and stops eating.

They quickly burn through their glucose, but they can't access their fat stores for backup energy and they can't even produce ketones as an alternative fuel.

They rapidly develop hypoketotic hypoglycemia, which can be fatal.

It's incredibly treatable just by ensuring they never go fasting, but you have to know to look for it.

Finally, let's cover our last categories dealing with mitochondria, peroxisomes and drug -induced disorders.

What's completely unique about mitochondrial disorders is the genetics.

Mitochondrial DNA is strictly maternal.

You only inherit it from your mother.

Furthermore, it lacks the standard DNA proofreading and repair mechanisms found in the nucleus, meaning its mutation rate is 10 to 100 times greater than nuclear DNA.

If you are suspecting a mitochondrial respiratory chain disorder, the key lab clue to look for is an arterial or venous lactate to pyruvate ratio that is incredibly high, greater than 50 to one.

Moving briefly to peroxisomal disorders, these are rare defects where the peroxisomes don't form properly or lack their enzymes.

A classic example is Zellweger syndrome, which presents with severe facial dysmorphia and profound liver disease.

And we must conclude with drug -induced inherited metabolic disorders.

We touched on this earlier.

A patient seems perfectly healthy their entire life until a specific drug unmasks their hidden genetic variant.

We mentioned succimothonium causing prolonged paralysis due to a plasma cholinesterase variant.

There's also primakine, an anti -malarial drug.

If you give this to someone with a G6PD enzyme deficiency, it triggers massive severe red blood cell hemolysis.

And halothane, a general anesthetic used in surgery, which can trigger malignant hyperpyrexia, a deadly rapid spike in body temperature and severe acidosis in genetically susceptible individuals.

To summarize our journey today, we've traced the path from a tiny singular alteration in the genetic blueprint down the metabolic assembly lines into the specific logical lab abnormalities they cause.

And finally to the clinical presentation you will see at the patient's bedside.

Whether it's screening newborns with a heel prick or deciphering a complex cascade of hypoglycemia and lactic acidosis, you now have the foundational framework to interpret these puzzles.

You really do.

You've got this.

And before we go, we want to leave you with a final lingering question to chew on, building off what we just learned about mitochondrial DNA.

Considering that mitochondrial DNA is inherited strictly from the mother and lacks a standard DNA repair mechanism, making its mutation rate up to 100 times greater than nuclear DNA, how might this incredibly high mutation rate naturally shape human evolution over millennia?

And what unique hurdles does it create for the future of targeted genetic therapies?

Something to ponder while you review your notes.

Thank you so much for joining us for this deep dive.

A warm supportive thank you from all of us here, your last minute lecture team.

Keep studying hard, trust your logic, and we will see you next time.